S. Karger AG

SHERPA: Unknown

People

  1. Abou-Alfa
    Abou-Alfa
  2. Janjigian
    Janjigian
  3. O'Reilly
    O'Reilly
  4. Ilson
    Ilson
  5. Saltz
    Saltz
  6. Cercek Hanjis
    Cercek Hanjis
  7. Molena
    Molena
  8. Raj
    Raj
  9. Bajorin
    Bajorin
  10. Bodei
    Bodei

Groups

  1. Department of Medicine (57)
  2. Gastrointestinal Oncology Service (57)
  3. Solid Tumor Oncology Division (57)
  4. Center for Pancreatic Cancer Research (15)
  5. Survivorship Research (5)
  6. Surgery (4)
  7. Weinberg Fellows (4)
  8. Graduate Medical Education (3)
  9. Biostatistics Service (2)
  10. Body Imaging Service (2)
Search Within
  1. "Gastrointestinal Oncology Service"
Formats
  1. Meeting Abstract (48)
  2. Journal Article (9)
Groups
  1. Department of Medicine (57)
  2. Gastrointestinal Oncology Service (57)
  3. Solid Tumor Oncology Division (57)
  4. Center for Pancreatic Cancer Research (15)
  5. Survivorship Research (5)
  6. Surgery (4)

More Groups

People
  1. Ghassan Abou-Alfa (18)
  2. Yelena Janjigian (12)
  3. Eileen O'Reilly (8)
  4. David Ilson (4)
  5. Diane Reidy (4)
  6. Andrea Cercek Hanjis (3)

More People

Years
  1. 2024 (7)
  2. 2023 (8)
  3. 2022 (6)
  4. 2021 (5)
  5. 2020 (10)
  6. 2019 (7)

More Years

Publications
  1. Oncology Research and Treatment (46)
  2. Neuroendocrinology (4)
  3. Oncology (4)
  4. Onkologie (2)
  5. Case Reports in Oncology (1)

Results (57)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
    Meeting Abstract

    Möhler, M.; Janjigian, Y.; Al-Batran, S. E.; Wainberg, Z.; Van Cutsem, E.; Molena, D.; Muro, K.; Hyung, W. J.; Wyrwicz, L.; Oh, D. Y.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate
    Meeting Abstract

    Möhler, M.; Janjigian, Y. Y.; Shitara, K.; Garrido, M.; Gallardo, C.; Shen, L.; Yamaguchi, K.; Wyrwicz, L.; Skoczylas, T.; Bragagnoli, A.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
    Meeting Abstract

    Sangro, B.; Chan, S. L.; Kelley, K.; Lau, G.; Kudo, M.; Sukeepaisarnjaroen, W.; De Toni, E.; Furuse, J.; Kang, Y. K.; Galle, P. R.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase 3 HIMALAYA study
    Meeting Abstract

    Vogel, A.; Chan, S. L.; Furuse, J.; Tak, W. Y.; Masi, G.; Varela, M.; Kim, J. H.; Tanasanvimon, S.; Reig, M.; Dayyani, F.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Impact of viral aetiology in the Phase 3 HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
    Meeting Abstract

    Chan, S. L.; Kudo, M.; Sangro, B.; Kelley, K.; Furuse, J.; Park, J. W.; Sunpaweravong, P.; Fasolo, A.; Yau, T.; Kawaoka, T.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer (MOUNTAINEER-03, trial in progress)
    Meeting Abstract

    Heinemann, V.; André, T.; Bekaii-Saab, T.; Cercek, A.; Nakamura, Y.; Raghav, K.; Siena, S.; Strickler, J.; Van Cutsem, E.; Adelberg, D.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Phase II, single-arm, open-label study of dostarlimab monotherapy in previously untreated patients with stage II/III dMMR/MSI-H locally advanced rectal cancer: Trial in progress
    Meeting Abstract

    Cercek, A.; Bachet, J. B.; Capdevilla, J.; Starling, N.; Chen, E.; Di Bartolomeo, M.; Yoshino, T.; Vlahovic, G.; Zografos, E.; O'donnell, S.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Adverse event profiles and time to onset and resolution with tremelimumab ( T) plus durvalumab (D) in patients with unresectable hepatocellular carcinoma (uHCC) in the phase 3 HIMALAYA trial
    Meeting Abstract

    De Toni, E. M.; Sangro, B.; Chan, S. L.; Kudo, M.; Kelley, R. K.; K, K. Y.; Rimassa, L.; Varela, M.; Dayyani, F.; Makowsky, M.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer (MOUNTAINEER-03, trial in progress)
    Meeting Abstract

    Heinemann, V.; Bekaii-Saab, T.; Van Cutsem, E.; Tabernero, J.; Siena, S.; Yoshino, T.; Nakamura, Y.; Raghav, K.; Cercek, A.; Adelberg, D.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649
    Meeting Abstract

    Moehler, M.; Janjigian, Y. Y.; Shitara, K.; Garrido, M.; Gallardo, C.; Shen, L.; Yamaguchi, K.; Wyrwicz, L.; Skoczylas, T.; Bragagnoli, A.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save